Summary

Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
Claus Niemann, MD
Photo of Claus Niemann
Claus Niemann

Description

Summary

In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to the liver.

Official Title

PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver

Keywords

Hepatitis C Transplantation Disease Transmission Sofosbuvir Velpatasvir Sofosbuvir-velpatasvir drug combination Sofosbuvir/Velpatasvir Sofosbuvir/Velpatasvir/Voxilaprevir

Eligibility

You can join if…

  • Adult (≥ 18 year-old), wait-listed for primary kidney or liver transplant without a potential suitable living donor or for simultaneous liver kidney transplant;
  • HCV non-infected at the time of transplant. Subjects who were previously HCV infected but who have had documented SVR12 are eligible to participate;
  • Agree to use two methods of birth control during the study;
  • Donor characteristics: serum HCV NAT-positive and negative for hepatitis B surface antigen. For liver transplant: pre-donation liver biopsy with no fibrosis (F0) or minimal fibrosis (F1). For kidney transplant: kidney donor profile index < 85%.

You CAN'T join if...

  • Donor and/or recipient HIV infection
  • Subject pregnant or nursing
  • Donor and/or recipient Hepatitis B surface antigen positive
  • Kidney-pancreas transplant
  • Single organ liver recipients who received hemodialysis for more than 7 days prior to liver transplantation
  • Kidney recipients: on dialysis for > 5 years at time of Screening; subjects sensitized with panel reactive antibody > 80%; for single organ kidney transplant, subjects with advanced liver fibrosis (Knodell stage 3) or cirrhosis
  • Individuals being treated with and needing to continue rifabutin, rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, St. John's wort (Hypericum perforatum), medium- or high-dose rosuvastatin or atorvastatin, or high-dose proton pump inhibitors (See Concomitant Medications).
  • Individuals treated with amiodarone within 42 days of organ transplant.

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • University of Colorado Denver
    Aurora Colorado 80045 United States

Lead Scientist at UCSF

  • Claus Niemann, MD
    My group is interested in identifying why obese individuals are at greater risk of liver injury in the setting of trauma or surgery. My long-term goal is to understand the relationship between metabolic and immunologic processes in the liver. One potential link between these underlying mechanisms could be the peptide leptin, which can profoundly modify inflammatory and metabolic pathways.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03619837
Phase
Phase 4
Study Type
Interventional
Last Updated